EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Baclofen 40 mg/20 mL in an Intrathecal Infusion System

Riccardo Marvulli iD, Serena Gervasi, Giuseppa Lagioia, Lucrezia Dell'Olio, Serena Caforio Montesardo iD, Marisa Megna iD, Maurizio Ranieri iD

Life · 14.03.2026 · 16 (3) · 473

DOI: 10.3390/life16030473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 14.03.2026. Verfasst von Riccardo Marvulli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, G. Cesare Place 11, 70125 Bari, Italy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Spasticity is a common feature of Upper Motoneuron Syndrome and is frequently treated with intrathecal baclofen (ITB) when oral therapy is ineffective or poorly tolerated. Different baclofen formulations are available for intrathecal use, but evidence regarding their clinical equivalence in patients requiring high daily doses remains limited.

Methods

Thirty adult patients (mean age 37 ± 5.8 years) receiving long-term ITB therapy were switched from four vials of baclofen 10 mg/5 mL to a single vial of baclofen 40 mg/20 mL, while maintaining the same total drug amount and reservoir concentration. Patients were divided into two groups: in 15 patients, the daily baclofen dose was maintained unchanged, while in the remaining 15 patients a 10% dose reduction was attempted. Clinical outcomes were assessed at baseline and during follow-up using validated scales for spasticity, pain, and functional status.

Results

In patients with unchanged daily dosing, no clinically relevant differences were observed in spasticity, pain, or functional independence after switching formulation, supporting clinical equivalence between the two preparations. Conversely, the 10% dose reduction proved clinically unsustainable in patients requiring high daily doses and required restoration of baseline dosing in all cases. No adverse events or formulation-related complications were observed.

Conclusions

Switching to baclofen 40 mg/20 mL is safe and clinically equivalent to the conventional 10 mg/5 mL formulation when the daily dose is maintained unchanged. Dose reduction appears unsuitable in patients requiring high daily intrathecal baclofen doses.

Schlagwörter

Stichwörter der Autor:innen

ITBUMSbaclofencerebral palsyefficacyintrathecal therapynetekasafetyspasticity

Autor:innen und Institutionen

  • Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, G. Cesare Place 11, 70125 Bari, Italy.

ORCID-Profile: Riccardo Marvulli, Serena Caforio Montesardo, Marisa Megna, Maurizio Ranieri

Zitieren

APA

Marvulli, R., Gervasi, S., Lagioia, G., Dell'Olio, L., Caforio Montesardo, S., Megna, M., & Ranieri, M. (2026). Efficacy and Safety of Baclofen 40 mg/20 mL in an Intrathecal Infusion System. Life, 16(3), 473. https://doi.org/10.3390/life16030473

Vancouver

Marvulli R, Gervasi S, Lagioia G, Dell'Olio L, Caforio Montesardo S, Megna M, et al. Efficacy and Safety of Baclofen 40 mg/20 mL in an Intrathecal Infusion System. Life. 2026;16(3):473. doi:10.3390/life16030473

BibTeX
@article{Marvulli2026,
  author = {Marvulli, Riccardo and Gervasi, Serena and Lagioia, Giuseppa and Dell'Olio, Lucrezia and Caforio Montesardo, Serena and Megna, Marisa and Ranieri, Maurizio},
  title = {Efficacy and Safety of Baclofen 40 mg/20 mL in an Intrathecal Infusion System},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {473},
  doi = {10.3390/life16030473}
}
Kostenlos starten →